Prevalence of <i>BRCA1</i> Promoter Methylation in Cohorts of Individuals With and Without Cancer Assessed by Circulating Cell-Free DNA

Our findings demonstrate that <i>BRCA1</i>meth can be robustly detected using cfDNA assessment both as a constitutional event in noncancer samples and as a metric of <i>BRCA1</i>meth tumor burden in individuals with <i>BRCA1</i>meth cancers. Therefore, the GRAIL assay provides a single quantitative platform that can be used to explore the role of <i>BRCA1</i>meth in cancer risk and therapeutic response.